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Abstract: Depression is one of the most important health problems worldwide. Women are 2.5 times
more likely to experience major depression than men. Evidence suggests that some women might
experience an increased risk for developing depression during “windows of vulnerability”, i.e., when
exposed to intense hormone fluctuations, such as the menopause transition. Indeed, this period
is associated with different symptoms, including vasomotor, depressive, and cognitive symptoms,
which have all been shown to worsen as women approach menopause. Even though hormonal
therapy represents the most effective treatment, side effects have been reported by several studies.
Therefore, an increased number of women might prefer the use of alternative medicine for treating
menopausal symptoms. N-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) are included
among these alternative treatments. We here provide a review of studies investigating the effects of n-3
LCPUFAs on hot flashes and depressive and cognitive disorders in menopausal women. The reported
results are scattered and heterogeneous. In conclusion, a beneficial role of n-3 LCPUFAs in hot flashes,
and depressive and cognitive symptoms related to menopausal transition is still far from conclusive.
Keywords: menopausal transition; perimenopause; omega-3; n-3 LCPUFAs; EPA; DHA; hot flashes;
depression; cognition; affective disorders
1. Introduction
Depression is a chronic mental disorder with several relapses or recurrences, that currently affects
350 million people worldwide [1]. Despite the increasing number of antidepressant drugs, current
treatment for depression will be effective for only 60% of patients [2]. For these reasons is important to
develop novel therapeutic strategies to treat depressed patients.
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Depression is much more common among women than men. Epidemiological data have showed
that women are 2.5 times more likely to suffer from major depression than men [3,4], with some women
appearing to be at higher risk during menopausal transition [5,6].
The terms perimenopause or menopausal transition, as defined by the latest consensus criteria for
staging of reproductive aging (STRAW + 10), cover the transition from the reproductive age through to
menopause and it is based on self-reported bleeding patterns. Perimenopause is characterized by three
steps: early menopausal transition (−2), persistent cycle irregularity, considered as ≥7 days difference
in length of consecutive cycles at least twice over the prior 10 cycles; late menopausal transition (−1),
an interval of amenorrhea of ≥60 days in the prior 12 months; early post menopause (+1a), the first
year following the final menstrual period (FMP) [7]. Indeed STRAW + 10 split out post menopause
in two subgroups: early post menopause (i.e., the first six years following the FMP) and late post
menopause (i.e., remaining lifespan) [7].
During the menopausal transition period, ovarian follicular functions reduce and subsequently
the levels of estrogens (estradiol and estrone) and progesterone first become fluctuating and finally
diminish, whereas levels of follicle stimulating hormone (FSH) increase [8,9]. These hormonal fluctuations
lead to menstrual cycle irregularity [9,10], vasomotor instability [11], and cognitive [12] and affective
changes [13–15].
Among the most invalidating symptoms of menopausal transition, there are hot flashes,
depressive, and cognitive symptoms [16]. Hot flashes affect up to 80% of women during the
menopausal transition and may last many years, ultimately compromising the quality of life [17].
Moreover, during the menopausal transition, the risk of onset of major depressive disorders (MDD)
increases [18,19] and mood symptoms arise, becoming persistent in 15% to 18% of perimenopausal
women, compared with 8% to 12% of premenopausal women [20].
Depression and hot flashes commonly co-occur during the menopausal transition, and women
with hot flashes are at increased risk for MDD [21]. Therefore, many data showed that perimenopause is
not only linked to a higher risk of depression but also to an impairment of cognitive functions [12,22–25].
Indeed, estrogens play an important role in promoting neuronal growth and survival [26], and it acts
especially on the prefrontal cortex [27–31]; as well, as it exerts an effect on the cholinergic system,
which is involved in cognitive functioning, especially memory [10,32].
Estrogens are also involved in the neurotransmitter systems implicated in the pathophysiology of
depression, acting as serotonergic agonists/modulators by increasing receptor binding sites, synthesis
and uptake both in animal models [33] and in post-menopausal women [34]. For these reasons, women
can improve their perimenopausal–related depression as well as depressive symptomatology using
estrogen therapy (ET) [35–38], which exerts a higher antidepressant effect in association with selective
serotonin reuptake inhibitor (SSRI) treatment [39].
Furthermore, several women in menopausal transition show an impairment of cognitive
functioning (e.g., forgetfulness and concentration difficulties), despite the weakness of the evidence
exploring this aspect [40].
Although substitutive hormonal therapy is considered the first line treatment for mood and
vasomotor symptoms menopause-related, a larger number of women tend to prefer alternative
therapies, particularly herbal supplements (e.g., isoflavones and black cohosh), or treatment with
selective serotonergic reuptake inhibitors (SSRIs), because of their reduced risks for health [17].
Nevertheless, most of these alternative medicines still remain understudied in the treatment of
MDD and menopausal symptoms.
Among these supplements, n-3 long-chain polyunsatured fatty acids (n-3 LCPUFAs) are one of
the most employed alternative therapies and are associated with other health benefits [41].
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Biologic Plausibility
The use of n-3 LCPUFAs in the menopausal period is derived from evidence showing that estrogens
stimulate, while testosterone inhibits, the conversion of essential fatty acids into their longer chain
metabolites, such as the case with α-linolenic acid conversion into docosahexaenoic acid (DHA) [42].
Omega-3 polyunsaturated fatty acid supplements mainly include gamma-linolenic acid (GLA),
eicosapentaenoic acid (EPA) and DHA, both derived from the precursor essential fatty acid (EFA)
alpha-linolenic acid (ALA), which are used for the treatment of several diseases (e.g., autoimmune
and cardiovascular diseases, psychiatric and cognitive disorders) because of their involvement in
numerous physiological functions, such as the composition of cell membrane structure and several cell
functions and responses [43].
The enzymatic metabolic byproducts of LCPUFAs are called eicosanoids and include
prostaglandins, thromboxanes, and leukotrienes. In particular, EPA-derived eicosanoids and products
from DHA (called docosanoids) may exert anti-inflammatory effects, therefore influencing the final
outcome of reactive processes [44].
Since n-3 LCPUFAs are incorporated into membrane phospholipids, the incorporation of DHA
takes place at a uniquely high level in the central nervous system, where phospholipids dominate
within the fat matrix [45]. A high-rate accumulation takes place in the brain starting in the brain
growth spurt during the intrauterine and neonatal period up to two years of age, and these high levels
are maintained throughout life [46], thus suggesting a continuous interaction with endogenous and
dietary pools through the whole life-span.
Accumulating data of increasing n-3 LCPUFAs use in psychiatry has a primary biological basis
in their neuroprotective properties, possibly producing modifications at the synaptic level [47].
Accordingly, n-3 LCPUFAs regulate brain cell signaling, including monoamine metabolism, and
are involved in the modification of receptor properties, or the activation of signal transduction by
receptors [48–51], at the basis of certain psychiatric diseases [52,53]. Human and animal studies
exploring the mechanism of action of n-3 LCPUFAs suggest the involvement of these supplements in
the modulation of serotonergic and dopaminergic neurotransmission [54–56].
The purpose of the present review is to synthesize the existing studies of the efficacy
and safety exerted by n-3 LCPUFAs supplementation in hot flashes, depressive, and cognitive
symptoms occurring during menopausal transition. Based on the abovementioned evidence it
seems that n-3 LCPUFAs might be useful either alone or as coadjuvant therapy for these disabling
perimenopausal symptoms.
2. Results
2.1. N-3 LCPUFAs in Menopausal Depressive and Cognitive Symptoms
Several epidemiological and observational studies suggest that a greater dietary intake of fish or a
n-3 LCPUFAs supplementation is related to a general reduced risk of developing depressive disorders
or fewer depressive symptoms [57,58]. Indeed, n-3 LCPUFAs exert their effects on cell membrane
fluidity [59] and impact on important neurophysiological pathways, mainly serotonin and dopamine
transmission, and their effects could be considered similar to those of selective serotonin reuptake
inhibitors (SSRIs) [60]. For these reasons n-3 LCPUFAs have been implicated in the aetiology and in
the treatment of different psychiatric disorders, in particular in MDD. Available data so far suggest
that purified EPA or EPA-enriched, rather than purified DHA or DHA-enriched supplements, alone or
as add-on therapy, are more beneficial in the treatment of MDD [61].
Furthermore, neuroimaging studies suggest that n-3 LCPUFAs promote cortical white matter
microstructural integrity [62], and a recent study found that the supplementation of n-3 LCPUFAs
increased white matter microstructural integrity and decreased depressive symptom severity in MDD
patients [63].
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It is of note that many incidence [64] and cross-sectional [58,65,66] studies with no fewer than
1300 participants have demonstrated an inverse correlation of n-3 LCPUFAs or fish with depressive
symptoms or disorders in women but not in men. This gender-specific association could be explained
by the estrogen–associated effects of n-3 LCPUFAs [67].
Specifically, menopausal depression show associations with previous Premenstrual Syndrome
(PMS) or postpartum depression; suffering of menopause side effects such as hot flashes, night sweats,
and insomnia; stress; weight gain; and low socio-economic level [68]. On the other hand, depressed
menopausal women are also exposed to a higher risk of developing osteoporosis, bone loss [69], and
cardiovascular disorders [70].
To clarify this issue, we carried out a review of all studies exploring the impact of n-3 LCPUFAs
on depression during menopausal transition (Table 1).
The first randomized control trial (RCT) study was conducted by Lucas et al. in 2009 [71] on a
sample of 120 postmenopausal women (aged 40–55 years old) with moderate-to-severe psychological
distress as measured by the Psychological General Well-Being (PGWB) Schedule, and with depressive
symptoms measured by the 20-item Hopkins Symptom Checklist Depression Scale (HSCL-D-20) and
by the 21-item Hamilton Depression Rating Scale (HAM-D-21), randomly assigned to receive EPA
(1.05 g/day) and DHA (0.25 g/day) or placebo for eight weeks.
At baseline only, a minority of depressed women (24%) satisfied the criteria for a major depressive
episode (MDE). After eight weeks, outcomes improved in both groups, without significant differences
between groups. Stratification analyses for MDE diagnosis showed that 8-week changes in psychological
distress and depressive scales improved significantly only in women with psychological distress
without MDE, but not in the MDE group. By contrast, Freeman at al. (2011) conducted an open
label study exploring the efficacy of n-3 LCPUFAs (eicosapentaenoic acid and docosahexaenoic acid,
2 g/day) for MDE associated with the menopausal transition. Twenty menopausal women (aged
44–50 years old) received eight weeks of treatment and their depressive symptoms were measured by
the Montgomery-Asberg Depression Rating Scale (MADRS). The authors showed that n-3 LCPUFAs
had a significant antidepressant effect according to a decreased MADRS scores. Interestingly, responders
had significantly lower pre-treatment docosahexaenoic acid levels than no responders. Despite the
small sample size and the lack of a placebo control group, this can be considered a positive study that
support the use of n-3 LCPUFAs for MDE during the menopausal transition [72].
In contrast, Cohen et al. (2014), in a larger multi-center RCT study, failed to demonstrate that
n-3 LCPUFAs improve mood in menopausal women compared to placebo. The authors administrated
1.8 g/day of n-3 LCPUFAs supplementation (3 pills/day each containing: 425 mg of EPA, 100 mg DHA,
and 90 mg of other omega-3s) or a placebo to a sample of 375 menopausal women (aged 40–62 years
old) for 12 weeks. Primary outcomes were vasomotor symptoms (VMS) frequency. Secondary outcomes
also included depressive symptoms as measured by the Physician’s Health Questionnaire-8 (PMQ-8).
However, in this sample only a very small proportion of women (8%) had substantial depressive symptoms
(PHQ-8 > 9), and therefore it was difficult to demonstrate the effect of n-3 LCPUFAs on mood [73].
Finally, we found only one RCT study exploring the combined effect of n-3 LCPUFAs and
SSRI (citalopram) for the treatment of 60 postmenopausal depressed women (aged 45–65 years
old) [74]. This is a triple-blind randomized controlled trial where the control group received 20 mg
citalopram plus a placebo, whereas the intervention group received 20 mg citalopram and 1 g of n-3
LCPUFAs for a week. Beck’s Depression Inventory (BDI) was administered at baseline, and at the
end of the first, second, and fourth weeks. A decreasing trend was observed in the mean depression
scores of the intervention group during the study, with mean depression scores of the intervention
group being significantly lower than the control group either two weeks or four weeks after the
treatments. Therefore, these results suggest that n-3 LCPUFAs can reduce the severity of depression in
post-menopausal women.
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Table 1. Randomized controlled trials (RCTs) of n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) on menopausal depressive and cognitive symptoms.
Depressive and
Cognitive Symptoms n Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
Study
[72] 19 postmenopausalwomen
Lovaza 2 g/day (1-g capsule: 465 mg
EPA + 375 mg DHA + 160 mg small
amounts of other omega-3
fatty acids)
8 weeks
The primary outcome was change in
depressive symptoms from beginning to
end of the study, as measured
by MADRS
The depressive symptoms
improved with treatment with a
significant decrease in
MADRS scores
[71]
120 post-menopausal
women omega-3s (n = 59)
or placebo (n = 61)
A 500-mg capsule three times daily
(350 mg of EPA and 50 mg of DHA in
the form of ethyl ester)
8 weeks
Primary outcome was to compare
enriched (E-EPA) supplementation with
placebo for the treatment of PD
measured by (PGWB) and depressive
symptoms measured by HSCL-D-20 and
HAM-D-21
Supplementation with E-EPA
omega-3 fatty acid improved
significantly more than placebo in
women with PD without MDE at
baseline, but not significantly in
women with PD and with MDE
[73]
355 post-menopausal
women were randomly
assigned to receive
omega-3s (n = 177) or
placebo (n = 178)
1.8 g/day of omega-3
supplementation (3 pills/day, each
containing 425 mg of EPA, 100 mg
DHA and 90 mg of other omega-3s)
12 weeks
The secondary outcomes were sleep
quality measured by (PSQI), insomnia
symptoms measured by (ISI), depressive
symptoms measured by (PHQ-8), and
anxiety measured by (GAD-7)
Omega-3s did not significantly
reduce sleep or mood compared
to placebo
[74]
60 postmenopausal
women: n = 30 citalopram
+ 1 g omega-3s and n = 30
citalopram + placebo
1 g/day of omega-3 fish oil capsules 4 weeks
The effect of a combination of omega-3
and citalopram in the treatment of
women with post-menopausal
depression measured by BDI
Omega-3s in combination with
citalopram demonstrated to
reduce the severity of depression
in post-menopausal wome
[75]
27 post-menopausal
women: n = 15 received
multinutrient
supplement) and n = 12
received placebo
Four capsules per day of Efalex
Active 50+, corresponding to: 1 g
DHA, 160 mg eicosapentaenoic acid,
240 mg Ginkgo biloba, 60 mg
phosphatidyl-serine, 20 mg d-α
tocopherol, 1 mg folic acid, and 20 µg
vitamin B12
24 weeks
The primary outcome measures were
based on changes in mobility (including
Habitual walking (HW), fast walking
(FW), and Vertical jump height (VJH)
and cognition (including psychomotor
response latency (MOT), Verbal
Recognition Memory (VRM), and paired
associate learning (PAL))
Multinutrient supplement
containing high doses of DHA
and eicosapentaenoic acid
significantly improves some
cognition and mobility measures
in post-menopausal women
DHA: Docosahexaenoic Acid; EPA: Eicosapentaenoic Acid; E-EPA: Ethyl-Eicosapentaenoic Acid; PD: Psychological Distress; MADRS: Montgomery-Asberg Depression Rating Scale; MDE :
major depressive episode; PGWBS : Psychological General Well-Being Schedule; HSCL-D-20: 20-item Hopkins Symptom Checklist Depression Scale; HAM-D-21: 21-item Hamilton
Depression Rating Scale:; PSQI :Pittsburg Sleep Quality Index; ISI: Insomnia Severity Index, PHQ-8: Physician’s Health Questionnaire-8; GAD-7: Generalized Anxiety Disorder-7; BDI:
Beck’s Depression Inventory.
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In conclusion, taken all together, these studies are not sufficient and powered enough to
suggest whether n-3 LCPUFAs, alone or as add-on therapy, are beneficial for the treatment of MDE.
However, better-designed and larger population-based studies are needed to clarify whether n-3
LCPUFAs are effective alone or in a synergistic way, combined with hormone therapy (HT) or SSRI, in
particular at specific doses.
With regards to the linkage between n-3 LCPUFAs and cognitive functions in humans,
several observational studies described a potential protective role of DHA in age-related cognitive
decline [76,77]. Based on these evidences, it has been reported a positive effect of DHA supplementation
on some cognitive outcome measures, such as Cambridge Neuropsychological Test Automated Battery
(CANTAB) Paired Associate Learning (PAL) and the cognitive portion of the Alzheimer’s Disease
Assessment Scale (ADAS-cog), in both healthy subjects, [78] and in patients with mild cognitive
impairment [79] or Alzheimer’s disease [80].
Despite great interest in the role of n-3 LCPUFAs in cognitive function preservation, just one RCT
evaluates the impact of n-3 LCPUFAs on age-related cognitive decline in post-menopausal women [75].
In this double-blind randomized controlled trial, 27 post-menopausal women were enrolled: the treated
arm (n = 15) received a multinutrient supplement called Efalex Active 5, corresponding to 1 g DHA, 160 mg
eicosapentaenoic acid, 240 mg Ginkgo biloba, 60 mg phosphatidyl-serine, 20 mg d-α tocopherol, 1 mg folic
acid, and 20 µg vitamin B12, while the second arm (n = 12) received a placebo throughout a period of
24 weeks. Both groups were evaluated for mobility outcome measures, including Habitual walking (HW),
Fast walking (FW), and Vertical jump height (VJH), and cognition outcome measures, including a battery
of computer-based cognitive tests (CANTAB, Cambridge Cognition Ltd.), the psychomotor response
latency “Motor Screening Task” (MOT), two memory tests, i.e., Verbal Recognition Memory (VRM), and
Paired Associate Learning (PAL), and one executive function test (Stockings of Cambridge). The results of
these assessments showed a significant improvement in two of the cognitive tests administered (MOT
and VRM), and in one of the three primary mobility measures (HW speed).
The findings of this pilot study motivate further clinical trials on wider populations, possibly
including women with cognitive impairment, to clarify the potential protective and therapeutic role of
LCPUFAs in cognitive symptoms menopause-related.
2.2. N-3 LCPUFAs in Menopausal Hot Flashes
Hot flashes (HFs) or VMS are the cardinal symptoms of menopause. HFs are mainly characterized
by a subjective sensation of heat that may be associated with sweating, cutaneous vasodilatation,
increased heart rate, and a subsequent drop in core temperature [81]. As far a possible biologic role,
n-3 LCPUFAs seem to affect serotonergic transmission, similar to antidepressants, which have been
demonstrated to diminish VMS [72]. However, the evidence that n-3 LCPUFAs may be efficacious for
the treatment of hot flashes are controversial.
In this paragraph, we provide an update regarding the effects of n-3 LCPUFAs supplementation
on VMS in menopausal women. We identified five RCT studies (Table 2).
A preliminary study by Freeman et al. (2011) evaluated the potential role of n-3 LCPUFAs
for MDE and VMS during the menopausal transition [72]. They found a significant improvement
in the mean frequency of hot flashes over a 24-h period with a significant decreased of Hot Flash
Related Daily Interference Scale (HFRDIS) scores, i.e., a 10-item self-report questionnaire that measures
the degree to which hot flashes interfere with daily activities and quality of life during the prior
week. Furthermore, participants who were responders to treatment, evaluated based on the scores
of depressive measures, were significantly more likely to have decreased hot flash diary scores than
non-responders. Similarly, the RCT by Lucas et al. (2009) found positive results. Specifically, after
eight weeks, HF frequency and scores decreased significantly in the Ethyl-Eicosapentaenoic (E-EPA)
group compared with the placebo group. In particular, the number of daily HFs decreased by a mean
of 1.58 (95% CI, −2.18 to −0.98), corresponding to 55% of the baseline value, in the E-EPA group and
by 0.50 (95% CI, −1.20 to 0.20) (25% of baseline value) in the placebo group [71].
Int. J. Mol. Sci. 2018, 19, 1849 7 of 14
Table 2. RCTs of n-3 LCPUFAs in menopausal hot flashes.
Hot Flashes and
Vasomotor Symptoms n Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
Study
[72] 19 women
Lovaza 2 g/day (1 g capsule: 465 mg
EPA + 375 mg DHA + 160 mg small
amounts of other omega-3
fatty acids)
8 weeks
The secondary outcome was change in
HF from beginning to end of the study,
as measured by hot flash diary and
HFRDIS scores
HF improved significantly with
treatment, as evident in hot flash
diary scores and HFRDIS scores
[71] E-EPA, n = 43; placebo,n = 39
A 500-mg capsule three times daily
(350 mg of EPA and 50 mg of DHA in
the form of ethyl ester)
8 weeks
Secondary objectives were to compare
the mean change in HFs (frequency,
intensity, and score) and the proportion
of HF responders (≥50% reduction in HF
frequency between baseline and week 8)
Supplementation with E-EPA
omega-3 fatty acid reduced HF
frequency and improved the HF
score relative to placebo
[73]
355 women were
randomly assigned to
receive omega-3s (n = 177)
or placebo (n = 178)
1.8 g/day of omega-3
supplementation (3 pills/day, each
containing 425 mg of EPA, 100 mg
DHA and 90 mg of other omega-3s)
12 weeks
The primary outcomes were VMS
frequency and bother based on daily
diaries at baseline and weeks 6 and 12
Omega-3s did not significantly
reduce hot flash frequency
compared to placebo (p = 0.28)
[82] 177 women to omega-3and 178 to placebo
1.8 g/day of omega-3 fish oil
capsules (425 mg E-EPA acid, 100 mg
DHA and 90 mg of other omega-3s
three times a day)
12 weeks
The MsFLASH Network, has conducted
three large RCTs for treatment of
menopausal VMS testing six
interventions including omega-3 fatty
acid supplementation
The MsFLASH 02 interventions
of yoga, exercise, and omega-3
showed little effect in reducing
vasomotor symptom frequency
or bother relative to control
[83] 355 women
1.8 g/day of omega-3 (425 mg E-EPA,
100 mg DHA and 90 mg of other
omega-3s)
12 weeks MENQOL total and domain (VMS,psychosocial, physical and sexual) scores
Hot flash interference, stress, pain
and sexual function showed no
improvement with exercise or
omega-3 interventions over usual
care or placebo, respectively
DHA: Docosahexaenoic Acid; EPA: Eicosapentaenoic Acid; E-EPA: Ethyl-Eicosapentaenoic Acid; HFRDIS: Hot Flash Related Daily Interference Scale scores; HF: hot flashes; VMS:
vasomotor symptoms; MENQOL: Menopausal Quality of Life Questionnaire.
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In contrast, a RCT study carried out by Cohen et al. (2014) testing the efficacy of omega-3s for
the reduction in frequency and bother of VMS in peri- and postmenopausal women found that this
supplementation did not significantly reduce hot flash frequency compared to placebo (p = 0.28) [73].
These results are reported also by Guthrie et al. (2015) in an analysis of pooled individual-level data
from three RCTs (MsFLASH 01, MsFLASH 02, MsFLASH 03) [82]. Finally, Reed et al. (2014) confirmed
that hot flash interference, stress, pain and sexual function showed no improvement with n-3 PUFAs
interventions over usual care or placebo [83].
In conclusion, large high-quality RCTs are still required to further clarify the role of n-3 LCPUFAs
on vasomotor symptoms in this population and to draw conclusions.
3. Materials and Methods
A comprehensive search on PUBMED of all trails using n-3 LCPUFAs on menopausal female
patients with depressive and cognitive symptoms, and vasomotor symptoms published up to April
2018 was performed.
Articles of potential interest were identified by using the following search terms: “omega-3“,
”polyunsaturated fatty acids”, “long-chain polyunsaturated fatty acids”, “PUFAs”, “LCPUFAs” “EPA”,
“DHA”, “docosahexaenoic acids”, “eicosapentaenoic acids” combined with the following term: “major
depressive disorder”, “affective disorder”, “depression”, “depressive symptoms”, “hot flashes”,
“vasomotor symptoms”, “cognitive disorder”, “cognitive symptoms”, “cognition” AND “menopausal
transition”, “perimenopausal”, “postmenopausal”, “menopause”. In this review, trials examining the
efficacy of n-3 LCPUFAs in menopausal women with depressive, cognitive, and vasomotor symptoms
were selected.
Trials were included if they examined the efficacy of n-3 LCPUFAs to target depressive or cognitive
disorders, and hot flashes in perimenopausal women.
We considered only trials in which the authors used an exposure of n-3 LCPUFAs as a
unique treatment or as an adjunctive therapy to other drugs (e.g., hormone replacement therapy,
antidepressants), or other no pharmacological strategies such as psychotherapy, physical exercise and
phytoestrogens, compared to placebo or pharmacotherapy alone.
To limit the heterogeneity of this review and to reduce selection biases, we decided to exclude:
trials examining the efficacy of n-3 LCPUFAs in subjects with others psychiatric diagnosis; trials
analyzing levels of n-3 LCPUFA; studies that did not explore the effects of n-3 LCPUFAs on depressive
or cognitive symptoms or hot flashes as primary outcome.
In addition, we excluded trials that employed a diet enriched in n-3 LCPUFAs as
a supplementation.
Among the 238 articles retrieved, 16 studies were identified and screened by reading the abstract,
and, when necessary, the full text, in order to select those articles relevant for the analysis. A manual
search of bibliographic cross-referencing complemented the search. Reference lists of relevant papers
were also inspected to identify any additional trials.
Relevant articles were obtained and included in the review if (a) they used an exposure of n-3
LCPUFAs; (b) included depressive, cognitive symptoms and hot flashes as an outcome measure and
(c) enrolled human participants and reported a trial.
The process of identification and inclusion of trials is summarized in Figure 1. Finally, eight trials
were included for the review. All searches, trial identification, data abstraction, and tabulation were
completed independently by eight researchers. Discordances were discussed and resolved.
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Figure 1. Preferred Reporting Items of Systematic reviews and Meta-Analyses (PRISMA) diagram: n-3
LCPUFAs supplementation in menopausal depressive and cognitive symptoms and hot flashes.
4. Conclusions and Future Direction
We have reviewed the effects of n-3 LCPUFAs in the treatment of hot flashes, and depressive and
cognitive disorders linked to menopausal transition (Table 3). The interest for this alternative therapy
raised from the evidence suggesting that the consumption of n-3 LCPUFAs has shown several beneficial
effects on chronic-degenerative disorders, including cardiovascular, metabolic, neuropsychiatric, and
inflammatory effects, which make it interesting for the women in menopausal transition.
Table 3. Effects of n-3 LCPUFAs supplementation in menopausal depressive and cognitive symptoms
and hot flashes: summary.
Menopausal Symptoms Positive Results Negative Results Positive Results withoutStatistical Significance
Hot flashes [71,82] [73,83] [72]
Depressive symptoms [74] [73] [71,72]
Cognitive symptoms [75]
Indeed, menopausal transition is accompanied by a number of symptoms of which hot flashes,
depression, irritability, difficulties in concentrating are the most frequent. These symptoms are linked
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to the reduced production of estrogen causing changes in thermoregulation and in the levels of
neurotransmitters, mainly serotonin. Our thorough overview of the literature has identified only a
number of trends. Firstly, the few trials conducted on this topic reported that n-3 LCPUFAs, alone or
added to other kind of pharmacological or no pharmacological interventions, might have the ability
to alleviate menopausal symptoms [71,72,74,82]. Secondly the available evidences also suggest that
the detection and treatment of n-3 LCPUFAs deficiency could be probably more effective in women
that showed pretreatment lower n-3 LCPUFAs plasma levels [72]. However, this hypothesis requires
future investigations. Thirdly, not all the available studies reported positive findings. Indeed, two
trials reported no effect of n-3 LCPUFAs on hot flashes and depressive symptoms [73,83]. This might
be probably due to the heterogeneity of the methods employed by the original studies, which often
had small and not homogeneous sample size, different selection criteria, different subtypes and dosage
of n-3 LCPUFAs (i.e., EPA, or DHA, or a combination of the two, or the addition of n-6 LCPUFAs as
well as various duration of supplementation).
Another relevant methodological limitation is represented by the multitask nature of the
neuropsychological tests and scales, leading to results not adjusted for multiple tests, which might
therefore limit the generalizability of the findings. Finally, no adverse effects related to the treatment
of n-3 LCPUFAs were observed in any of the clinical studies taken into account.
In conclusion, the lack of consistency across studies that have explored the n-3 LCPUFAs effects
in perimenopausal disorders implies the necessity of larger prospective interventional clinical studies
to elucidate the subtypes (EPA or DHA, or both types) and the therapeutic dose of n-3 LCPUFAs
required in these kinds of perimenopausal disorders. On a methodological standpoint newer and
more objective approaches should be used, either on an instrumental and a neurocognitive approach.
Spectrometry-based studies may represent a way to directly follow the metabolic fate of a specific
substrate towards a predicted function. These new approaches could help elucidate the wide-reaching
implications of n-3 LCPUFAs in health and disease.
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